Domingo Domènech, EvaGonzález Barca, EvaEstany, CarlaSureda, AnnaBesalduch, JoanFernández de Sevilla Ribosa, Alberto2020-12-152020-12-152002-11-010390-6078https://hdl.handle.net/2445/172746We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients.2 p.application/pdfeng(c) Ferrata Storti Foundation, 2002Anticossos monoclonalsÚs terapèuticLimfomesMonoclonal antibodiesTherapeutic useLymphomasinfo:eu-repo/semantics/article5190042020-12-15info:eu-repo/semantics/openAccess12414357